RT Journal Article
SR Electronic
T1 Epigenome-wide Association Study of Alcohol Use Disorder in Five Brain Regions
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.01.21261118
DO 10.1101/2021.08.01.21261118
A1 Lea Zillich
A1 Josef Frank
A1 Fabian Streit
A1 Marion M Friske
A1 Jerome C Foo
A1 Lea Sirignano
A1 Stefanie Heilmann-Heimbach
A1 Helene Dukal
A1 Franziska Degenhardt
A1 Per Hoffmann
A1 Anita C Hansson
A1 Markus M Nöthen
A1 Marcella Rietschel
A1 Rainer Spanagel
A1 Stephanie H Witt
YR 2021
UL http://medrxiv.org/content/early/2021/10/19/2021.08.01.21261118.abstract
AB Alcohol Use Disorder (AUD) is closely linked to the brain regions forming the neurocircuitry of addiction. Postmortem human brain tissue enables the direct study of the molecular pathomechanisms of AUD. This study aims to identify these mechanisms by examining differential DNA-methylation between cases with severe AUD (n=53) and controls (n=58) using a brain region-specific approach, in which sample sizes ranged between 46 and 94. Samples of the anterior cingulate cortex (ACC), Brodmann Area 9 (BA9), caudate nucleus (CN), ventral striatum (VS), and putamen (PUT) were investigated. DNA-methylation levels were determined using the Illumina HumanMethylationEPIC Beadchip. Epigenome-wide association analyses were carried out to identify differentially methylated CpG-sites and regions between cases and controls in each brain region. Weighted Correlation Network Analysis (WGCNA), gene-set and GWAS-enrichment analyses were performed. Two differentially methylated CpG-sites were associated with AUD in the CN, and 18 in VS (q <.05). No epigenome-wide significant CpG-sites were found in BA9, ACC, or PUT. Differentially methylated regions associated with AUD case-/control status (q < .05) were found in the CN (n=6), VS (n=18) and ACC (n=1). In the VS, the WGCNA-module showing the strongest association with AUD was enriched for immune-related pathways. This study is the first to analyze methylation differences between AUD cases and controls in multiple brain regions and consists of the largest sample to date. Several novel CpG-sites and regions implicated in AUD were identified, providing a first basis to explore epigenetic correlates of AUD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by the German Federal Ministry of Education and Research (BMBF), A systems-medicine approach towards distinct and shared resilience and pathological mechanisms of substance use disorders (01ZX01909 to Rainer Spanagel, Marcella Rietschel, Stephanie H Witt, Anita C Hansson), Towards Targeted Oxytocin Treatment in Alcohol Addiction (Target-OXY) (031L0190A to Jerome C Foo). ERA-NET program: Psi-Alc (FKZ: 01EW1908), and the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - Project-ID 402170461 - TRR 265 to Rainer Spanagel, Anita C Hansson and Marcella RietschelAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Informed consent has been obtained by the New South Wales Tissue Ressource Centre. Samples were received under study reference number 2009-238N-MA by the Ethics Committee II of the Medical Faculty Mannheim. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data and summary statistics for all analyses are available on request.